Papers
4
Total Citations
63
H-Index
4
About
Ben Vanneste is a leading urologic oncologist whose research centers on optimizing treatment for prostate cancer, particularly through advanced imaging and surgical innovation. His most impactful work demonstrates how prostate-specific membrane antigen (PSMA) PET/CT imaging significantly improves outcomes for men with biochemically recurrent prostate cancer undergoing salvage radiation therapy—a finding with over 30 citations that has reshaped clinical decision-making. Vanneste has also developed a novel, evidence-based management algorithm for radiation-induced urethritis and cystitis, providing clinicians with a practical framework for treating these challenging complications. His expertise extends to surgical technique, where he has rigorously evaluated the safety and feasibility of transitioning from standard anterior to Retzius-sparing robot-assisted radical prostatectomy, showing that this approach can be implemented without compromising oncologic outcomes. Most recently, Vanneste created and internally validated a nomogram that predicts salvage radiation therapy success specifically for patients without metastases on PSMA PET/CT, enabling more personalized treatment planning. With a growing body of work that bridges imaging, surgery, and survivorship care, Vanneste is advancing precision medicine in prostate cancer management while directly improving patient quality of life.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4